2018
Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers
Johnson S, Park H, Gross C, Yu J. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e399-e400. DOI: 10.1016/j.ijrobp.2018.07.1180.Peer-Reviewed Original ResearchComplementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers
Johnson SB, Park HS, Gross CP, Yu JB. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA Oncology 2018, 4: 1375-1381. PMID: 30027204, PMCID: PMC6233773, DOI: 10.1001/jamaoncol.2018.2487.Peer-Reviewed Original ResearchConceptsConventional cancer treatmentsUse of CMOverall survivalComplementary medicineHormone therapyTreatment delayCharlson-Deyo comorbidity scoreCancer treatmentCancer-accredited centersNational Cancer DatabaseCharacteristics of patientsYear of diagnosisRetrospective observational studyConventional cancer therapiesHigh refusal rateRace/ethnicityNonmetastatic breastComorbidity scorePatient characteristicsCurable cancerEntire cohortColorectal cancerCancer DatabaseInsurance typeObservational study
2017
Use of Alternative Medicine for Cancer and Its Impact on Survival
Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. Journal Of The National Cancer Institute 2017, 110: djx145. PMID: 28922780, DOI: 10.1093/jnci/djx145.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBreast NeoplasmsChoice BehaviorColorectal NeoplasmsComorbidityComplementary TherapiesEducational StatusFemaleHumansIncomeLung NeoplasmsMaleNeoplasm StagingNorthwestern United StatesPacific StatesPatient PreferenceProstatic NeoplasmsResidence CharacteristicsSex FactorsSurvival RateConceptsConventional cancer treatmentsAlternative medicineColorectal cancerCox proportional hazards regressionGreater riskLower comorbidity scoreMultivariable logistic regressionProportional hazards regressionPatterns of utilizationHigher socioeconomic statusNonmetastatic breastComorbidity scoreHormone therapyCurable cancerHazards regressionLung cancerAM useAnticancer treatmentStage IICancerIndependent covariatesLogistic regressionPatientsCancer treatmentSocioeconomic status